Sugi Predict

Sugi Predict / Compounds / SCHEMBL21672036

SCHEMBL21672036

SCHEMBL21672036

Nc1ccc(N2CCC3(COC3)C2)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ LMNA P02545 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ GAA P10253 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CYP11B1 P15538 2/20 0.37
▸ CYP11B2 P19099 2/20 0.37
▸ PDE3B Q13370 1/20 0.35
▸ PDE3A Q14432 1/20 0.35
▸ TTK P33981 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ RORC P51449 1/20 0.34
▸ CNR2 P34972 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18410807 0.88 MAPT (0.49) MAPTALDH1A1LMNAMAPK1GFER
SCHEMBL22852515 0.78 ALDH1A1 (0.55) MAPTALDH1A1LMNAMAPK1GFER
SCHEMBL21835147 0.78 ALDH1A1 (0.55) MAPTALDH1A1LMNAMAPK1GAA
SCHEMBL1749853 0.77 ALDH1A1 (0.48) MAPTALDH1A1LMNAMAPK1GFER
SCHEMBL23126590 0.77 MAPT (0.54) MAPTALDH1A1LMNAMAPK1GFER
SCHEMBL3011234 0.75 ALDH1A1 (0.59) MAPTALDH1A1LMNAMAPK1GFER
SCHEMBL19302970 0.75 LRRK2 (0.46) MAPTALDH1A1LMNAMAPK1GFER
SCHEMBL22852534 0.75 MAPT (0.49) MAPTALDH1A1LMNAMAPK1GFER
SCHEMBL24301057 0.75 MAPT (0.49) MAPTALDH1A1LMNAMAPK1GFER
SCHEMBL21634966 0.74 ATR (0.38) MAPTALDH1A1LMNAMAPK1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528810-B2 Small molecule inhibitors of DYRK/CLK and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2026-01-20 — — US disclosed
US-20250051325-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2025-02-13 — — US disclosed
US-12054483-B2 Small molecule inhibitors of DYRK/CLK and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2024-08-06 — — US disclosed
US-20220041590-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2022-02-10 — — US disclosed
US-20200039989-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2020-02-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528810-B2 Small molecule inhibitors of DYRK/CLK and uses thereof CLK3, CLK2, CLK1 MAPT 890/4885ALDH1A1 3885/4885LMNA 3740/4885
US-20200039989-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK1, CLK3 MAPT 341/4885ALDH1A1 2781/4885LMNA 3111/4885
US-20220041590-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK1, CLK3 MAPT 341/4885ALDH1A1 2781/4885LMNA 3111/4885
US-12054483-B2 Small molecule inhibitors of DYRK/CLK and uses thereof CLK2, CLK1, CLK3 MAPT 341/4885ALDH1A1 2781/4885LMNA 3111/4885
US-20250051325-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK1, CLK3 MAPT 341/4885ALDH1A1 2781/4885LMNA 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.